Ajouter à une liste

Communiqués Kineta, Inc. Nasdaq

Actions

KANT

US49461C1027

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/09/2024			Varia. 5j.	Varia. 1 janv.
0,5746 ^USD	-30,69%		-25,61%	-84,17%

01/07/25	Kineta, Inc. annonce des changements au sein de son conseil d'administration	CI
15/05/25	Kineta, Inc. publie ses résultats financiers pour le premier trimestre clos le 31 mars 2025	CI

Communiqués

12/12/24	Kineta : TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.	PU
25/11/24	TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update Form 8 K	PU
08/11/24	Kineta : Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer Form 8 K	PU
08/11/24	Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)	AQ
08/10/24	Kineta : Announces Completion of Enrollment in the Monotherapy Arm of the VISTA 101 Phase 1 Clinical Study in Advanced Solid Tumors Form 8 K	PU
08/10/24	Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors	AQ
04/10/24	Kineta : Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 Form 8 K	PU
04/10/24	Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024	AQ
03/10/24	Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking Antibody Currently in Phase 1	AQ
02/10/24	Kineta : Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 Form 8 K	PU
02/10/24	Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !